Suppliers and packagers for generic pharmaceutical drug: soybean oil

soybean oil

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Fresenius	INTRALIPID 10%	soybean oil	INJECTABLE;INJECTION	017643	NDA	Baxter Healthcare CORP	0338-0518-12	250 mL in 1 BAG (0338-0518-12)	2014-12-12
Fresenius	INTRALIPID 10%	soybean oil	INJECTABLE;INJECTION	017643	NDA	Baxter Healthcare CORP	0338-0518-13	500 mL in 1 BAG (0338-0518-13)	2014-12-12
Fresenius	INTRALIPID 10%	soybean oil	INJECTABLE;INJECTION	017643	NDA	Baxter Healthcare CORP	0338-0518-58	100 mL in 1 BAG (0338-0518-58)	2014-12-12

Soybean Oil Drug Supplier Landscape: Who Supplies Refined Soybean Oil for Pharmaceutical Use?

Last updated: June 1, 2026

Which companies supply pharmaceutical-grade soybean oil for drug manufacturing?

Soybean oil is generally sourced through industrial and food-ingredient supply chains, then qualified for pharmaceutical excipient use (or for non-active manufacturing inputs). In pharma, the supplier set typically splits into (1) excipient-grade soybean oil providers (often under ISO/FDA-aligned quality systems) and (2) commodity soybean oil producers that can qualify lots to pharmacopoeial/technical specifications through controlled documentation, testing, and change controls.

Most common supplier archetypes in pharma qualification

• Refined soybean oil producers supplying bulk oil for excipient and processing needs.
• Excipient ingredient suppliers that repackage, blend, or distribute soybean oil with documented specifications and COA traceability.
• Contract manufacturers and distributors offering regulatory-facing documentation (DMFs when applicable for associated components/processes, batch traceability, and quality agreements).

Practical note for qualification For “pharmaceutical-grade” soybean oil, buyers typically require:

• controlled refining process description and impurity profile
• compliance to relevant pharmacopeial monographs (where applicable to use)
• allergen handling controls (soy)
• change notification and batch traceability
• stability and retest specifications per incoming material program

What specifications determine whether soybean oil is acceptable for pharma use?

Typical quality gates used in pharmaceutical procurement

• Refining level: neutralized, deodorized, bleached (exact process controls depend on end use).
• Impurity profile: free fatty acids, peroxide value/oxidation markers, residual solvents where relevant, sterols content where specified by the buyer.
• Micro/biological: often controlled via supplier process and buyer incoming testing plan.
• Allergen and residuals: soy allergen management is standard; additional residual contaminant controls depend on market requirements.
• Regulatory alignment: excipient status depends on the specific monograph and intended use (excipient vs. processing aid).

Where soybean oil is used in pharma supply chains

• Excipients or vehicle oils in formulation development (depending on product).
• Processing inputs in manufacturing steps (depending on the product and process).
• Packaging-related migration studies may require defined oil grades.

How do pharmaceutical buyers qualify soybean oil suppliers?

Supplier qualification workflow

1. Document review: COA templates, specs, GMP statement, traceability, change control, allergen controls.
2. Quality agreements: audit rights, deviation/CAPA handling, complaint management, recall support.
3. Lot qualification: at least 3 consecutive lots used in the buyer’s incoming specs with stability/retest plan.
4. Ongoing verification: periodic incoming testing and trend monitoring.

Common hard requirements

• consistent refining parameters or validated “equivalent” process
• master lot traceability (origin, refining facility, batch number)
• validated test methods or accredited testing per buyer spec

Which soybean oil suppliers dominate the global commodity supply chain relevant to pharma?

For pharma procurement, dominance usually tracks the global refined soybean oil market, since many excipient suppliers source from large refiners and then qualify or distribute the material.

Major global refiners and ingredient processors commonly referenced in industrial supply

• Bunge
• Cargill
• Wilmar
• Archer Daniels Midland (ADM)
• Louis Dreyfus Company
• Olam/ingredient arms (varies by region and product)
• IOI/related food-ingredient refiners (regional presence differs)

These groups can supply bulk refined soybean oil, subject to qualification for the buyer’s specification and intended regulatory use.

Which regional suppliers matter most for sourcing soybean oil for pharma manufacturing?

United States

• Large refiners operate on industrial commodity supply, then provide excipient-grade documentation when contracted.
• Procurement typically blends: direct bulk supply plus qualified distributors for consistent paperwork and lot traceability.

Europe

• Similar industrial supply dominance; excipient-grade availability often comes via ingredient distributors and refiners with strong documentation.

Asia-Pacific

• Supply is heavily regionally sourced; qualification depends on the refining facility and the availability of consistent impurity profiles.

What sourcing risks exist for soybean oil, and how do buyers mitigate them?

Key risks

• Oxidation variability across batches: soybean oil is oxidation-sensitive; peroxide value and related markers can drift with time/transport conditions.
• Impurity drift tied to crude origin and refining yield adjustments.
• Regulatory documentation gaps: commodity refiners may not provide excipient-grade paperwork without a structured quality agreement.
• Supply concentration: bulk soybean oil has concentrated refining capacity in certain regions.

Mitigations used in pharma

• tighter incoming specification controls and accelerated retest scheduling
• temperature/light exclusion in transport and storage
• chain-of-custody and master lot traceability enforcement
• formal change control for supplier process or crude sourcing changes

How does soybean oil excipient sourcing compare with other vegetable oils (palm, canola, sunflower) in pharma?

Procurement comparability

• Similar qualification approach (impurity profile, oxidation, monograph compliance, documentation).
• Differences usually come from:
  • oxidation stability and antioxidant practices
  • impurity markers specific to oil type and refining process
  • availability and pricing volatility by origin and refining region

Competitive implication If a formulation requires tight oxidation stability, buyers often prefer suppliers with demonstrated oxidation trend control and documented stabilization approaches (if allowed by the formulation).

---

Key Takeaways

• Pharmaceutical “soybean oil” supply typically comes from refined commodity producers qualified under excipient-style documentation and impurity controls, plus distributors that package and manage regulatory-facing paperwork.
• Supplier selection is driven by spec adherence (oxidation and impurity profile), lot traceability, and quality agreements, not branding.
• Major global refiners such as Bunge, Cargill, Wilmar, ADM, and Louis Dreyfus are often the practical upstream sources, then get qualified for pharma use through structured procurement.

FAQs

1. What COA items are most critical for soybean oil in pharma incoming release?
   Oxidation markers (e.g., peroxide-related measures), free fatty acids, impurity profile, origin/lot traceability, and micro-related results per buyer spec.

2. Can a commodity soybean oil supplier be qualified for pharmaceutical excipient use?
   Yes if the supplier provides GMP-aligned quality systems, controlled change management, and consistent specs with lot traceability suitable for the buyer’s qualification program.

3. What causes batch-to-batch variation in refined soybean oil?
   Crude origin, refining parameter changes, storage/transport oxidation exposure, and differences in deodorization intensity.

4. What storage conditions reduce soybean oil oxidation risk for pharma lots?
   Control temperature and light exposure, minimize headspace/oxygen exposure where feasible, and enforce FIFO with retest scheduling.

5. Is soybean oil typically covered by DMFs or excipient master files?
   Coverage depends on the specific regulatory strategy and grade. Many cases rely on supplier COA/spec plus quality agreements; DMFs are more common for specific formulation-relevant intermediates or regulated substances than for bulk excipient commodities.

---

References (APA)

1. European Pharmacopoeia. (n.d.). General methods of analysis for oils and related products.
2. U.S. Food and Drug Administration. (n.d.). Guidance for industry: Pharmaceutical cGMPs for excipients.
3. Codex Alimentarius. (n.d.). Food additives and contaminants: general guidance on specification and purity.